Julika Pitsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julika Pitsch has a total of 415 co-authors. Here are the top co-authors by number of shared publications:
Albert J. Becker
Institute of Cellular Neurosciences II, University Hospital Bonn, Bonn, Germany
12 shared publications- Albert J. Becker
Medical Faculty, Institute of Cellular Neurosciences II University of Bonn Bonn Germany
9 shared publications Susanne Schoch
Institute of Cellular Neurosciences II, University Hospital Bonn Bonn Germany
9 shared publicationsRainer Surges
Department of Epileptology University Hospital Bonn Bonn Germany
7 shared publications- Rainer Surges
Department of Epileptology, University Hospital Bonn, Germany
7 shared publications - Susanne Schoch
Institute of Cellular Neurosciences II, Medical Faculty, University of Bonn, Bonn, Germany
6 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Wiley in Annals of Neurology
T Cell‐Mediated Targeting of Interneurons in Mice Shapes Hippocampal Remodeling and Epilepsy
Objective: Autoimmune encephalitis (AE) is associated with autoantibodies targeting distinct neuronal populations. In AE, antibodies against glutamate decarboxylase 65 (GAD65), expressed in GABAergic interneurons, are frequently detected. In GAD65‐AE, hippocampal biopsies often show infiltrates of CD8 + cytotoxic T cells (CTLs), suggesting a prominent T cell‐associated pathology. This has led to the hypothesis that CTLs contribute to neuronal injury in GABAergic circuits. We investigated whether selective CTL‐mediated dysfunction of hippocampal interneurons may contribute to temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS). Methods: We developed a mouse model based on virus‐mediated expression of ovalbumin (OVA) selectively in CA1 hippocampal interneurons into transgenic mice harboring OVA‐specific CD8 + T cells. This approach enables interneuron‐specific immune targeting within the hippocampus. Results: Interneuron‐specific OVA expression in hippocampal CA1 resulted in rapid CD8 + T cell infiltration and targeting of inhibitory neuronal populations, accompanied by acute symptomatic seizures beginning 4 to 6 days after transduction. This acute inflammation‐associated phase was followed by a chronic phase characterized by persistent spontaneous recurrent seizures (SRS), HS, sustained microglial activation, and astrogliosis. In the chronic stage, reduced Reelin expression coincided with interneuron vulnerability, granule cell dispersion (GCD), and mossy fiber reorganization. Proliferation analyses suggest that GCD results from displacement of pre‐existing granule cells rather than aberrant neurogenesis, and is associated with gliosis and reduced Reelin expression. Interpretation: These findings demonstrate that selective CTL‐mediated targeting of hippocampal CA1 interneurons induces seizures and hippocampal remodeling. This model shapes current concepts of epileptogenesis by showing that cell type‐specific autoimmune mechanisms recapitulate key features of TLE, including GCD. ANN NEUROL 2026
- 2 September 2026
- Published by Wiley in Annals of Neurology
Open AccessT Cell‐Mediated Targeting of Interneurons in Mice Shapes Hippocampal Remodeling and Epilepsy
Objective: Autoimmune encephalitis (AE) is associated with autoantibodies targeting distinct neuronal populations. In AE, antibodies against glutamate decarboxylase 65 (GAD65), expressed in GABAergic interneurons, are frequently detected. In GAD65‐AE, hippocampal biopsies often show infiltrates of CD8 + cytotoxic T cells (CTLs), suggesting a prominent T cell‐associated pathology. This has led to the hypothesis that CTLs contribute to neuronal injury in GABAergic circuits. We investigated whether selective CTL‐mediated dysfunction of hippocampal interneurons may contribute to temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS). Methods: We developed a mouse model based on virus‐mediated expression of ovalbumin (OVA) selectively in CA1 hippocampal interneurons into transgenic mice harboring OVA‐specific CD8 + T cells. This approach enables interneuron‐specific immune targeting within the hippocampus. Results: Interneuron‐specific OVA expression in hippocampal CA1 resulted in rapid CD8 + T cell infiltration and targeting of inhibitory neuronal populations, accompanied by acute symptomatic seizures beginning 4 to 6 days after transduction. This acute inflammation‐associated phase was followed by a chronic phase characterized by persistent spontaneous recurrent seizures (SRS), HS, sustained microglial activation, and astrogliosis. In the chronic stage, reduced Reelin expression coincided with interneuron vulnerability, granule cell dispersion (GCD), and mossy fiber reorganization. Proliferation analyses suggest that GCD results from displacement of pre‐existing granule cells rather than aberrant neurogenesis, and is associated with gliosis and reduced Reelin expression. Interpretation: These findings demonstrate that selective CTL‐mediated targeting of hippocampal CA1 interneurons induces seizures and hippocampal remodeling. This model shapes current concepts of epileptogenesis by showing that cell type‐specific autoimmune mechanisms recapitulate key features of TLE, including GCD. ANN NEUROL 2026
- Open Access
Hippocampal network activity changes during early epileptogenesis predict subsequent epilepsy
Objective: Despite decades of research, the circuit mechanisms that underlie focal epileptogenesis remain incompletely understood. In this study, we aimed to characterize the changes in hippocampal network activity induced by an epileptogenic insult. Methods: In rats, prolonged electrical perforant pathway stimulation leads in a high percentage of animals to the development of temporal lobe epilepsy. However, a subset of animals remained apparently non‐epileptic for unknown reasons. We monitored alterations of neuronal activity by chronically recording the local field potential (LFP) from the hippocampal dentate gyrus before, during, and after the potentially epileptogenic insult and quantifying the time‐dependent changes in the periodic and the aperiodic components of the LFP. Results: It is intriguing that animals with epilepsy identified by subsequent spontaneous epileptic seizures were characterized by a transient increase in the aperiodic exponent, suggesting a shift toward a reduced local excitation‐to‐inhibition (E/I) ratio during the first days after the perforant path stimulation. Furthermore, these animals developed a strong impairment of theta oscillation prevalence and regularity during early epileptogenesis. In contrast, resilient non‐epilepsy animals without spontaneous seizures showed neither this modulation in E/I ratio nor a corruption of hippocampal theta activity. In fact, the increase in the aperiodic exponent on the first day after completion of the electrical stimulation paradigm could predict epileptogenesis with very high fidelity (area under the curve [AUC] 0.92) and correlated significantly with later seizure rate. Significance: The very early phase of epileptogenesis seems to be dominated by a relative dominance of inhibitory synaptic activity in affected circuits. This finding opens the opportunity to dissect mechanisms of epileptogenesis and to test the effectiveness of anti‐epileptogenesis treatment in very early disease stages by allowing identification of individuals at high risk. Furthermore, it might offer a potential explanation for the frequently observed failure of anti‐epileptogenesis drugs boosting γ‐aminobutyric acid (GABA)ergic inhibition.
Open AccessHippocampal network activity changes during early epileptogenesis predict subsequent epilepsy
Objective: Despite decades of research, the circuit mechanisms that underlie focal epileptogenesis remain incompletely understood. In this study, we aimed to characterize the changes in hippocampal network activity induced by an epileptogenic insult. Methods: In rats, prolonged electrical perforant pathway stimulation leads in a high percentage of animals to the development of temporal lobe epilepsy. However, a subset of animals remained apparently non‐epileptic for unknown reasons. We monitored alterations of neuronal activity by chronically recording the local field potential (LFP) from the hippocampal dentate gyrus before, during, and after the potentially epileptogenic insult and quantifying the time‐dependent changes in the periodic and the aperiodic components of the LFP. Results: It is intriguing that animals with epilepsy identified by subsequent spontaneous epileptic seizures were characterized by a transient increase in the aperiodic exponent, suggesting a shift toward a reduced local excitation‐to‐inhibition (E/I) ratio during the first days after the perforant path stimulation. Furthermore, these animals developed a strong impairment of theta oscillation prevalence and regularity during early epileptogenesis. In contrast, resilient non‐epilepsy animals without spontaneous seizures showed neither this modulation in E/I ratio nor a corruption of hippocampal theta activity. In fact, the increase in the aperiodic exponent on the first day after completion of the electrical stimulation paradigm could predict epileptogenesis with very high fidelity (area under the curve [AUC] 0.92) and correlated significantly with later seizure rate. Significance: The very early phase of epileptogenesis seems to be dominated by a relative dominance of inhibitory synaptic activity in affected circuits. This finding opens the opportunity to dissect mechanisms of epileptogenesis and to test the effectiveness of anti‐epileptogenesis treatment in very early disease stages by allowing identification of individuals at high risk. Furthermore, it might offer a potential explanation for the frequently observed failure of anti‐epileptogenesis drugs boosting γ‐aminobutyric acid (GABA)ergic inhibition.
- Open Access
- 7 July 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Forkhead box versus NF-κB hippocampal snRNA-seq profiles distinguish anti-Drebrin- and anti-GAD65-positive encephalitis
Background and objectives: Autoantibodies (ABs) against intracellular proteins, including glutamate-decarboxylase 65 (anti-GAD65), are increasingly recognized in autoimmune and limbic encephalitis (AE/LE). Anti-GAD65 LE frequently progresses to severe temporal lobe epilepsy (TLE), neuropathologically characterized by hippocampal sclerosis (HS) and variable infiltration of cytotoxic T lymphocytes (CTLs). Recently, we have identified Drebrin (DBN) as a new intracellular target protein of ABs in index patients with suspected AE. Here, we aim to characterize key molecular and cellular signatures of hippocampal tissue from anti-GAD65- (GAD65-TLE) versus anti-DBN-positive TLE (DBN-TLE) patients correlated to clinical parameters. Methods: We examined hippocampal neuropathology and performed exploratory single-nucleus RNA sequencing (snRNA-seq) of hippocampal tissue from DBN- and GAD65-TLE patients, integrated with key clinical data from a large patient cohort. Results: Although the hippocampi of the two patient groups were neuropathologically virtually indistinguishable, exploratory snRNA-seq revealed distinct transcriptional programs. DBN-TLE patients ( n = 2) showed transcriptional signatures enriched for forkhead box (Fox) transcription factor family, whereas GAD65-TLE patients ( n = 2) displayed transcriptional signatures enriched for transcripts related to NF-κB- signaling. In a larger cohort, DBN-TLE patients ( n = 22) showed significantly more favorable pharmacological responsiveness than GAD65-TLE patients ( n = 35), who were largely pharmacoresistant. Notably, in a T cell-mediated mouse model for LE, similar inflammatory programs were dynamically regulated. Conclusion: These findings provide a discovery-based transcriptomic signatures of rare autoimmune hippocampal tissue, revealing distinct immune-associated transcriptional states in anti-DBN- versus anti-GAD65-positive AE/TLE patients despite virtually indistinguishable hippocampal pathology in both groups and support further investigations of disease-specific therapeutic strategies.
- 7 July 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Open AccessForkhead box versus NF-κB hippocampal snRNA-seq profiles distinguish anti-Drebrin- and anti-GAD65-positive encephalitis
Background and objectives: Autoantibodies (ABs) against intracellular proteins, including glutamate-decarboxylase 65 (anti-GAD65), are increasingly recognized in autoimmune and limbic encephalitis (AE/LE). Anti-GAD65 LE frequently progresses to severe temporal lobe epilepsy (TLE), neuropathologically characterized by hippocampal sclerosis (HS) and variable infiltration of cytotoxic T lymphocytes (CTLs). Recently, we have identified Drebrin (DBN) as a new intracellular target protein of ABs in index patients with suspected AE. Here, we aim to characterize key molecular and cellular signatures of hippocampal tissue from anti-GAD65- (GAD65-TLE) versus anti-DBN-positive TLE (DBN-TLE) patients correlated to clinical parameters. Methods: We examined hippocampal neuropathology and performed exploratory single-nucleus RNA sequencing (snRNA-seq) of hippocampal tissue from DBN- and GAD65-TLE patients, integrated with key clinical data from a large patient cohort. Results: Although the hippocampi of the two patient groups were neuropathologically virtually indistinguishable, exploratory snRNA-seq revealed distinct transcriptional programs. DBN-TLE patients ( n = 2) showed transcriptional signatures enriched for forkhead box (Fox) transcription factor family, whereas GAD65-TLE patients ( n = 2) displayed transcriptional signatures enriched for transcripts related to NF-κB- signaling. In a larger cohort, DBN-TLE patients ( n = 22) showed significantly more favorable pharmacological responsiveness than GAD65-TLE patients ( n = 35), who were largely pharmacoresistant. Notably, in a T cell-mediated mouse model for LE, similar inflammatory programs were dynamically regulated. Conclusion: These findings provide a discovery-based transcriptomic signatures of rare autoimmune hippocampal tissue, revealing distinct immune-associated transcriptional states in anti-DBN- versus anti-GAD65-positive AE/TLE patients despite virtually indistinguishable hippocampal pathology in both groups and support further investigations of disease-specific therapeutic strategies.
- Open Access
Pyruvate dehydrogenase autoantibodies in autoantibody‐negative patients with seizures are associated with reduced pyruvate dehydrogenase activity
Objective: We investigated the presence and potential functional relevance of antimitochondrial autoantibodies in patients suspicious for autoimmune encephalitis (AIE) associated with psychiatric symptoms and/or seizures, who were negative for known antineuronal autoantibodies. Methods: We screened serum samples from 387 patients autoantibody‐negative for known antineuronal autoantibodies with psychiatric disturbances and/or epileptic seizures, including patients with temporal lobe epilepsy of unknown etiology. Various techniques, including immunoblotting, immunoprecipitation, mass spectrometry, immunohistochemistry, and in vitro assays assessing neuronal autoantibody uptake, neuronal viability, pyruvate dehydrogenase (PDH) enzyme activity, and mitochondrial DNA levels in biofluids were applied. Results: Mass spectrometry detected all three subunits of the intramitochondrial PDHc—pyruvate dehydrogenase, dihydrolipoyl acetyltransferase, and dihydrolipoyl dehydrogenase—as targets of antibodies present in serum samples from three index patients suspicious for AIE with psychiatric symptoms or seizures. The presence of the anti‐PDHc autoantibodies was confirmed by immunoblotting in 12 of 387 patients. Exposure of cultured primary neurons to commercial anti‐PDH antibodies resulted in neuronal uptake and loss of neuronal viability. Patient‐derived autoantibodies also impaired PDH enzyme activity in vitro. Additionally, cell‐free mitochondrial DNA fragment levels were elevated in the serum and cerebrospinal fluid of PDH‐positive patients compared to controls. Significance: Anti‐PDH autoantibodies were detected in patients suspicious for AIE with seizures and/or psychiatric symptoms as core manifestation in the absence of known antineuronal autoantibodies. These autoantibodies bind neuronal structures and reduce PDH enzyme activity under experimental conditions, supporting mechanistic plausibility of a functional role in disease.
Open AccessPyruvate dehydrogenase autoantibodies in autoantibody‐negative patients with seizures are associated with reduced pyruvate dehydrogenase activity
Objective: We investigated the presence and potential functional relevance of antimitochondrial autoantibodies in patients suspicious for autoimmune encephalitis (AIE) associated with psychiatric symptoms and/or seizures, who were negative for known antineuronal autoantibodies. Methods: We screened serum samples from 387 patients autoantibody‐negative for known antineuronal autoantibodies with psychiatric disturbances and/or epileptic seizures, including patients with temporal lobe epilepsy of unknown etiology. Various techniques, including immunoblotting, immunoprecipitation, mass spectrometry, immunohistochemistry, and in vitro assays assessing neuronal autoantibody uptake, neuronal viability, pyruvate dehydrogenase (PDH) enzyme activity, and mitochondrial DNA levels in biofluids were applied. Results: Mass spectrometry detected all three subunits of the intramitochondrial PDHc—pyruvate dehydrogenase, dihydrolipoyl acetyltransferase, and dihydrolipoyl dehydrogenase—as targets of antibodies present in serum samples from three index patients suspicious for AIE with psychiatric symptoms or seizures. The presence of the anti‐PDHc autoantibodies was confirmed by immunoblotting in 12 of 387 patients. Exposure of cultured primary neurons to commercial anti‐PDH antibodies resulted in neuronal uptake and loss of neuronal viability. Patient‐derived autoantibodies also impaired PDH enzyme activity in vitro. Additionally, cell‐free mitochondrial DNA fragment levels were elevated in the serum and cerebrospinal fluid of PDH‐positive patients compared to controls. Significance: Anti‐PDH autoantibodies were detected in patients suspicious for AIE with seizures and/or psychiatric symptoms as core manifestation in the absence of known antineuronal autoantibodies. These autoantibodies bind neuronal structures and reduce PDH enzyme activity under experimental conditions, supporting mechanistic plausibility of a functional role in disease.
- Open Access
Hippocampal network activity changes during early epileptogenesis predict subsequent epilepsy
The circuit mechanisms underlying focal epileptogenesis are, despite of decades of epilepsy research, still incompletely understood. In this study, we aimed to characterize the changes in hippocampal network activity induced by a potentially epileptogenic insult. In rats, long-lasting electrical perforant pathway stimulation leads in a high percentage of animals to the development of temporal lobe epilepsy. However, a subset of animals remains resilient against the stimulation. We monitored alterations of neuronal activity by chronically recording the local field potential (LFP) from the hippocampal dentate gyrus before, during and after the potentially epileptogenic insult. Intriguingly, epilepsy animals identified by subsequent spontaneous epileptic seizures were characterized by a transient increase in the aperiodic exponent suggesting a shift towards a reduced local excitation-to-inhibition (E/I) ratio during the first days after the perforant path stimulation. Furthermore, these animals developed a strong impairment of theta oscillation prevalence and regularity during early epileptogenesis. In contrast, resilient non-epilepsy animals without spontaneous seizures neither showed this modulation in E/I ratio nor a corruption of hippocampal theta activity. In fact, the increase in the aperiodic exponent on the first day after completion of the electrical stimulation paradigm could predict epileptogenesis with very high fidelity (AUC 0.92) and correlated significantly with later seizure rate. This finding opens the opportunity to dissect mechanisms of epileptogenesis and to test the effectiveness of anti-epileptogenesis treatment in very early disease stages by allowing identification of individuals at high risk. Furthermore, it might offer a potential explanation for the frequently observed failure of anti-epileptogenesis drugs boosting GABAergic inhibition.
Open AccessHippocampal network activity changes during early epileptogenesis predict subsequent epilepsy
The circuit mechanisms underlying focal epileptogenesis are, despite of decades of epilepsy research, still incompletely understood. In this study, we aimed to characterize the changes in hippocampal network activity induced by a potentially epileptogenic insult. In rats, long-lasting electrical perforant pathway stimulation leads in a high percentage of animals to the development of temporal lobe epilepsy. However, a subset of animals remains resilient against the stimulation. We monitored alterations of neuronal activity by chronically recording the local field potential (LFP) from the hippocampal dentate gyrus before, during and after the potentially epileptogenic insult. Intriguingly, epilepsy animals identified by subsequent spontaneous epileptic seizures were characterized by a transient increase in the aperiodic exponent suggesting a shift towards a reduced local excitation-to-inhibition (E/I) ratio during the first days after the perforant path stimulation. Furthermore, these animals developed a strong impairment of theta oscillation prevalence and regularity during early epileptogenesis. In contrast, resilient non-epilepsy animals without spontaneous seizures neither showed this modulation in E/I ratio nor a corruption of hippocampal theta activity. In fact, the increase in the aperiodic exponent on the first day after completion of the electrical stimulation paradigm could predict epileptogenesis with very high fidelity (AUC 0.92) and correlated significantly with later seizure rate. This finding opens the opportunity to dissect mechanisms of epileptogenesis and to test the effectiveness of anti-epileptogenesis treatment in very early disease stages by allowing identification of individuals at high risk. Furthermore, it might offer a potential explanation for the frequently observed failure of anti-epileptogenesis drugs boosting GABAergic inhibition.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200469
Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis
Autoimmune encephalitis (AIE) with anti-leucine-rich glioma-inactivated 1 (LGI1) antibodies typically manifests with subacute cognitive deficits, seizures, and psychiatric symptoms, mostly in older adults. Immunotherapy (IT) leads to the cessation of seizures in most patients, yet some develop AIE-associated epilepsy (AEAE) and persistent cognitive deficits. The aim of this large multicentric retrospective observational cohort study was to assess long-term outcomes of patients with anti-LGI1 encephalitis regarding seizures and AEAE and to identify associated factors. We included patients with anti-LGI1 encephalitis from 3 national referral centers/consortia meeting the following inclusion criteria: (I) definite LGI1 limbic encephalitis (Graus criteria); (II) occurrence of seizures; and (III) follow-up period ≥24 months. We aimed to (1) determine the risk of seizure recurrence (ROSR) on remission, (2) investigate clinical and paraclinical biomarkers for an effect on time to seizure remission using Cox proportional hazard modeling (n = 188), and (3) assess the risk of AEAE and determine associated factors (n = 236). AEAE was observed in 5.9% (16/271) of the full cohort. Both AEAE (16/16 vs 129/215, p = 0.001) and longer time to seizure remission (OR 1.36 per year, p = 0.025) were associated with persistent cognitive impairment. Patients with pilomotor seizures had a lower rate of seizure remission (hazard ratio [HR] 0.58, 95% CI 0.55-0.60, p < 0.001) while patients under IT administration had a higher rate of seizure remission over time (HR 12.4, 95% CI 9.67-16.0, p < 0.001). In addition, patients receiving second-line IT tended to achieve earlier seizure remission (log-rank test, p = 0.019). The ROSR at 12, 60, and 120 months on seizure remission was 9% (95% CI 4.5%-13%), 20% (95% CI 11%-28%), and 53% (95% CI 14%-74%), respectively. In conclusion, our results demonstrate that AEAE in anti-LGI1 encephalitis is rare and suggest that the diagnosis of epilepsy is inappropriate in patients reaching seizure remission because of a relatively low ROSR. Accordingly, on seizure remission, the diagnosis of acute symptomatic seizures would be appropriate. Moreover, we validate and quantify the importance of IT for seizure remission and identify biomarkers associated with lower rates of seizure remission. Late remission of seizures and AEAE were associated with persistent cognitive impairment.
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200469
Open AccessRisk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis
Autoimmune encephalitis (AIE) with anti-leucine-rich glioma-inactivated 1 (LGI1) antibodies typically manifests with subacute cognitive deficits, seizures, and psychiatric symptoms, mostly in older adults. Immunotherapy (IT) leads to the cessation of seizures in most patients, yet some develop AIE-associated epilepsy (AEAE) and persistent cognitive deficits. The aim of this large multicentric retrospective observational cohort study was to assess long-term outcomes of patients with anti-LGI1 encephalitis regarding seizures and AEAE and to identify associated factors. We included patients with anti-LGI1 encephalitis from 3 national referral centers/consortia meeting the following inclusion criteria: (I) definite LGI1 limbic encephalitis (Graus criteria); (II) occurrence of seizures; and (III) follow-up period ≥24 months. We aimed to (1) determine the risk of seizure recurrence (ROSR) on remission, (2) investigate clinical and paraclinical biomarkers for an effect on time to seizure remission using Cox proportional hazard modeling (n = 188), and (3) assess the risk of AEAE and determine associated factors (n = 236). AEAE was observed in 5.9% (16/271) of the full cohort. Both AEAE (16/16 vs 129/215, p = 0.001) and longer time to seizure remission (OR 1.36 per year, p = 0.025) were associated with persistent cognitive impairment. Patients with pilomotor seizures had a lower rate of seizure remission (hazard ratio [HR] 0.58, 95% CI 0.55-0.60, p < 0.001) while patients under IT administration had a higher rate of seizure remission over time (HR 12.4, 95% CI 9.67-16.0, p < 0.001). In addition, patients receiving second-line IT tended to achieve earlier seizure remission (log-rank test, p = 0.019). The ROSR at 12, 60, and 120 months on seizure remission was 9% (95% CI 4.5%-13%), 20% (95% CI 11%-28%), and 53% (95% CI 14%-74%), respectively. In conclusion, our results demonstrate that AEAE in anti-LGI1 encephalitis is rare and suggest that the diagnosis of epilepsy is inappropriate in patients reaching seizure remission because of a relatively low ROSR. Accordingly, on seizure remission, the diagnosis of acute symptomatic seizures would be appropriate. Moreover, we validate and quantify the importance of IT for seizure remission and identify biomarkers associated with lower rates of seizure remission. Late remission of seizures and AEAE were associated with persistent cognitive impairment.
- 17 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (816) , eadv3260
Hippocampal spreading depolarization as a driver of postictal ambulation
Postseizure (postictal) symptoms are regularly encountered in epilepsy and can be life threatening, yet their neurobiological underpinnings remain understudied. Using two-photon or widefield imaging, field potential and unit recordings, optogenetics, and basic behavioral assessment under healthy conditions or viral encephalitis, we studied seizures and postictal symptoms in mice. We show a propensity of the hippocampus for seizure-associated spreading depolarization (sSD). Through optogenetic stimulation, we provide evidence that induced isolated hippocampal SD is sufficient to elicit postictal ambulation (PIA), whereas induced isolated seizure-like episodes are not. Furthermore, PIA occurred in the absence of SD progression to the neocortex. In addition, we analyzed Behnke-Fried depth-electrode recordings in four patients with focal epilepsy. Of 13 recorded seizures, we observed five slow shifts at seizure termination in the regionwise analysis that could reflect putative sSD. In support of our experiments in mice, we also found an increased vulnerability of the human temporomesial system (hippocampus and amygdala) for this phenomenon and longer recovery times of affected as compared with nonaffected brain regions. This work suggests sSD as a previously underrecognized pathoclinical entity underlying distinct postictal symptoms in epilepsy.
- 17 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (816) , eadv3260
Hippocampal spreading depolarization as a driver of postictal ambulation
Postseizure (postictal) symptoms are regularly encountered in epilepsy and can be life threatening, yet their neurobiological underpinnings remain understudied. Using two-photon or widefield imaging, field potential and unit recordings, optogenetics, and basic behavioral assessment under healthy conditions or viral encephalitis, we studied seizures and postictal symptoms in mice. We show a propensity of the hippocampus for seizure-associated spreading depolarization (sSD). Through optogenetic stimulation, we provide evidence that induced isolated hippocampal SD is sufficient to elicit postictal ambulation (PIA), whereas induced isolated seizure-like episodes are not. Furthermore, PIA occurred in the absence of SD progression to the neocortex. In addition, we analyzed Behnke-Fried depth-electrode recordings in four patients with focal epilepsy. Of 13 recorded seizures, we observed five slow shifts at seizure termination in the regionwise analysis that could reflect putative sSD. In support of our experiments in mice, we also found an increased vulnerability of the human temporomesial system (hippocampus and amygdala) for this phenomenon and longer recovery times of affected as compared with nonaffected brain regions. This work suggests sSD as a previously underrecognized pathoclinical entity underlying distinct postictal symptoms in epilepsy.
- Open Access
- 26 July 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-18
Coexistence of CN1A autoantibodies in GAD65 encephalitis exacerbates neurodegeneration
Background: Autoantibodies targeting the intracellular 65-kDa isoform of glutamic acid decarboxylase (anti-GAD65) have been associated with a variety of autoimmune-related syndromes involving a spectrum of difficult-to-treat neurological disorders. However, the pathophysiological role of anti-GAD65 in neuroinflammation remains vague. Its understanding may be complicated by the possible pathogenic interaction between anti-GAD65 and potentially coexisting autoantibodies. Methods: We combined a broad spectrum of approaches ranging from antibody-antigen identification, immunoblotting, immunoprecipitation, mass-spectrometry, cell-based assays, subcellular binding pattern analysis in primary neuronal cultures, and immunohistochemistry to in vitro assays of neuronal uptake, viability, and multi-electrode arrays. Results: In anti-GAD65-positive neurological patients, mass-spectrometric analysis revealed cytosolic 5’-nucleotidase 1 A (CN1A syn. NT5C1A) as the most abundant antigen. Subsequent screening of 118 anti-GAD65-positive patients revealed that 32 of them had additional autoantibodies targeting CN1A, which were also present in all available corresponding CSF samples. Limbic encephalitis was more often diagnosed in anti-CN1A/anti-GAD65-positive compared to the anti-GAD65-positive patients. Functionally, incubation of primary hippocampal neurons with anti-GAD65, but not with anti-CN1A, resulted in uptake into GABAergic neurons, neuronal cell death, and increased neuronal network activity. Moreover, simultaneous incubation with both antibodies (anti-CN1A/anti-GAD65) resulted in concomitant intraneuronal uptake in a concentration-dependent manner, which correlated with enhanced autophagy followed by massive neuronal death. Conclusion: GAD65 antibodies directly affect neuronal viability and network activity. Co-existing autoantibodies against CN1A, present in anti-GAD65-positive patients, enhance autophagy and subsequent neuronal death in vitro. Clinically, anti-GAD65-positive patients should be screened for anti-CN1A-associated diseases, and evaluation of anti-CN1A in anti-GAD65-related autoimmune conditions may clarify links between systemic autoimmunity and epilepsy.
- 26 July 2025
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-18
Open AccessCoexistence of CN1A autoantibodies in GAD65 encephalitis exacerbates neurodegeneration
Background: Autoantibodies targeting the intracellular 65-kDa isoform of glutamic acid decarboxylase (anti-GAD65) have been associated with a variety of autoimmune-related syndromes involving a spectrum of difficult-to-treat neurological disorders. However, the pathophysiological role of anti-GAD65 in neuroinflammation remains vague. Its understanding may be complicated by the possible pathogenic interaction between anti-GAD65 and potentially coexisting autoantibodies. Methods: We combined a broad spectrum of approaches ranging from antibody-antigen identification, immunoblotting, immunoprecipitation, mass-spectrometry, cell-based assays, subcellular binding pattern analysis in primary neuronal cultures, and immunohistochemistry to in vitro assays of neuronal uptake, viability, and multi-electrode arrays. Results: In anti-GAD65-positive neurological patients, mass-spectrometric analysis revealed cytosolic 5’-nucleotidase 1 A (CN1A syn. NT5C1A) as the most abundant antigen. Subsequent screening of 118 anti-GAD65-positive patients revealed that 32 of them had additional autoantibodies targeting CN1A, which were also present in all available corresponding CSF samples. Limbic encephalitis was more often diagnosed in anti-CN1A/anti-GAD65-positive compared to the anti-GAD65-positive patients. Functionally, incubation of primary hippocampal neurons with anti-GAD65, but not with anti-CN1A, resulted in uptake into GABAergic neurons, neuronal cell death, and increased neuronal network activity. Moreover, simultaneous incubation with both antibodies (anti-CN1A/anti-GAD65) resulted in concomitant intraneuronal uptake in a concentration-dependent manner, which correlated with enhanced autophagy followed by massive neuronal death. Conclusion: GAD65 antibodies directly affect neuronal viability and network activity. Co-existing autoantibodies against CN1A, present in anti-GAD65-positive patients, enhance autophagy and subsequent neuronal death in vitro. Clinically, anti-GAD65-positive patients should be screened for anti-CN1A-associated diseases, and evaluation of anti-CN1A in anti-GAD65-related autoimmune conditions may clarify links between systemic autoimmunity and epilepsy.
- 27 May 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213629
Association of Cortical Atrophy Patterns With Clinical Phenotypes and Histopathological Findings in Patients With Rasmussen Syndrome
Automated MRI analyses have identified variable patterns of cortical atrophy in Rasmussen syndrome. In this study, we aim to identify imaging phenotypes of Rasmussen syndrome, to clinically characterize these phenotypes, and to validate this imaging-based approach through histopathologic analysis. For this retrospective case-control study, individuals with Rasmussen syndrome diagnosed according to the European Consensus Statement and at least one 3D T1-weighted MRI scan (k-means clustering. Neuropsychological test results and results from neuropathologic analyses of biopsies were ascertained, and correlations between subtype-specific atrophy maps and normative maps (enhancing neuro imaging genetics through meta analysis [ENIGMA] and neuromaps toolbox) were used to characterize atrophy profiles and epicenter susceptibility. The study incorporated 54 individuals with Rasmussen syndrome (median age at MRI: 18 years, range 2-61, 65% female) and 270 healthy individuals (median age at MRI: 26.5 years, range 3-61, 49% female). Four distinct atrophy subtypes were identified (temporoparietal, centrotemporal, frontal, and bilateral). Individuals with the centrotemporal subtype were younger at onset (median 5.5 years) than individuals with temporoparietal (median 11.5 years, p = 0.02) and frontal (median 6 years, p = 0.02) subtypes. Most severe neuropsychological impairment was observed for the temporoparietal and frontal subtypes. In the temporoparietal and frontal subtypes, atrophy occurred preferentially in hubs (r = -0.28, p = 0.006; r = -0.30, p = 0.02). Disease epicenter susceptibility was associated with higher cortical thickness (r = -0.57, p = 0.005), lower myelin content (r = 0.47, p = 0.02), lower cerebral blood flow (r = 0.42, p = 0.03), lower blood volume (r = 0.57, p = 0.006), and lower oxygen metabolism (r = 0.47, p = 0.01). Brain biopsies showing strong inflammation were taken from likely epicenters, whereas biopsies with weaker inflammation came from less likely epicenters (p = 0.04). Using Rasmussen syndrome as a model, we validate imaging-based mapping of individual disease epicenters with histopathologic evidence. With further validation, network-based mapping of individual disease epicenters could potentially be used in Rasmussen syndrome to guide biopsy site selection, inform treatment decisions, and improve outcome prognoses.
- 27 May 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213629
Association of Cortical Atrophy Patterns With Clinical Phenotypes and Histopathological Findings in Patients With Rasmussen Syndrome
Automated MRI analyses have identified variable patterns of cortical atrophy in Rasmussen syndrome. In this study, we aim to identify imaging phenotypes of Rasmussen syndrome, to clinically characterize these phenotypes, and to validate this imaging-based approach through histopathologic analysis. For this retrospective case-control study, individuals with Rasmussen syndrome diagnosed according to the European Consensus Statement and at least one 3D T1-weighted MRI scan (k-means clustering. Neuropsychological test results and results from neuropathologic analyses of biopsies were ascertained, and correlations between subtype-specific atrophy maps and normative maps (enhancing neuro imaging genetics through meta analysis [ENIGMA] and neuromaps toolbox) were used to characterize atrophy profiles and epicenter susceptibility. The study incorporated 54 individuals with Rasmussen syndrome (median age at MRI: 18 years, range 2-61, 65% female) and 270 healthy individuals (median age at MRI: 26.5 years, range 3-61, 49% female). Four distinct atrophy subtypes were identified (temporoparietal, centrotemporal, frontal, and bilateral). Individuals with the centrotemporal subtype were younger at onset (median 5.5 years) than individuals with temporoparietal (median 11.5 years, p = 0.02) and frontal (median 6 years, p = 0.02) subtypes. Most severe neuropsychological impairment was observed for the temporoparietal and frontal subtypes. In the temporoparietal and frontal subtypes, atrophy occurred preferentially in hubs (r = -0.28, p = 0.006; r = -0.30, p = 0.02). Disease epicenter susceptibility was associated with higher cortical thickness (r = -0.57, p = 0.005), lower myelin content (r = 0.47, p = 0.02), lower cerebral blood flow (r = 0.42, p = 0.03), lower blood volume (r = 0.57, p = 0.006), and lower oxygen metabolism (r = 0.47, p = 0.01). Brain biopsies showing strong inflammation were taken from likely epicenters, whereas biopsies with weaker inflammation came from less likely epicenters (p = 0.04). Using Rasmussen syndrome as a model, we validate imaging-based mapping of individual disease epicenters with histopathologic evidence. With further validation, network-based mapping of individual disease epicenters could potentially be used in Rasmussen syndrome to guide biopsy site selection, inform treatment decisions, and improve outcome prognoses.
- Open Access
- 19 June 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 128, 48-53
Focused review: Clinico-neuropathological aspects of late onset epilepsies
- 19 June 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 128, 48-53
Open AccessFocused review: Clinico-neuropathological aspects of late onset epilepsies